Kidney Function and Lipid Levels in Older Adults: The Atherosclerosis Risk in Communities Study
Shreya Srivastava, MD, MPH, Josef Coresh, MD, PhD, Casey M. Rebholz, PhD, MS, MNSP, MPH and 4 more
Kidney Medicine · 2022
doi:10.1016/j.xkme.2022.100494 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Cardiovascular disease is a leading cause of mortality among older adults in the United States.1Virani S.S. Alonso A. Aparicio H.J. et al.Heart disease and stroke statistics—2021 update: a report from the American Heart Association.Circulation. 2021; 143: e254-e743Crossref PubMed Scopus (2810) Google Scholar Both chronic kidney disease (CKD) and dyslipidemia—important risk factors of cardiovascular disease—are common among older adults.2Chronic Kidney Disease in the United States, 2021. US Department of Health and Human Services, Centers for Disease Control and Prevention.https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.htmlDate accessed: November 22, 2021Google Scholar,3McDonald M. Hertz R.P. Unger A.N. Lustik M.B. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older.J Gerontol A Biol Sci Med Sci. 2009; 64: 256-263Crossref PubMed Scopus (192) Google Scholar Although there have been studies examining dyslipidemia in CKD among young and middle-aged adults, there is a paucity of literature on lipid levels by CKD stage in older adults. Serum creatinine is the most common filtration marker used for estimated glomerular filtration rate (eGFR), the primary measure of kidney function. However, serum creatinine may overestimate kidney function in older adults because it is affected by nonkidney determinants, such as muscle mass and protein intake.4Inker L.A. Schmid C.H. Tighiouart H. et al.Estimating glomerular filtration rate from serum creatinine and cystatin C.N Engl J Med. 2012; 367: 20-29Crossref PubMed Scopus (2727) Google Scholar An eGFR determined using both serum creatinine and cystatin C provides more accurate estimates.4Inker L.A. Schmid C.H. Tighiouart H. et al.Estimating glomerular filtration rate from serum creatinine and cystatin C.N Engl J Med. 2012; 367: 20-29Crossref PubMed Scopus (2727) Google Scholar In this study, we sought to examine the associations between eGFR on the basis of both creatinine and cystatin C and lipid levels in older adults. We conducted a cross-sectional analysis of adults aged 67-89 years during visit 5 (2011-2013) of the Atherosclerosis Risk in Communities study. Among 6,538 individuals from visit 5, those without data on eGFR, statin use, or covariates were excluded. The final study population was 4,965 individuals (Fig S1). The eGFR was calculated using the 2021 CKD Epidemiology Collaboration creatinine-cystatin C equation without a race coefficient.5Inker L.A. Eneanya N.D. Coresh J. et al.New creatinine- and cystatin C–based equations to estimate GFR without race.N Engl J Med. 2021; 385: 1737-1749Crossref PubMed Scopus (697) Google Scholar Lipid parameters of interest included total cholesterol; low-density lipoprotein cholesterol (LDL-C), calculated via the Friedewald method; high-density lipoprotein cholesterol (HDL-C); and triglyceride (TG). We plotted adjusted lipid levels by eGFR levels from multivariable linear regression models with linear splines and 3 knots at eGFR 90, 60, and 45 mL/min/1.73 m2. We also examined binary outcomes (total cholesterol ≥200 mg/dL; LDL-C ≥100 mg/dL; HDL-C <50 mg/dL; and TG ≥150 mg/dL),1Virani S.S. Alonso A. Aparicio H.J. et al.Heart disease and stroke statistics—2021 update: a report from the American Heart Association.Circulation. 2021; 143: e254-e743Crossref PubMed Scopus (2810) Google Scholar using multivariable logistic regression with eGFR categories (<45, 45-60, >60 mL/min/1.73 m2).6KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int Suppl. 2013; 3: 30-130Google Scholar Covariates included age, sex, race-center, body mass index, history of coronary artery disease, diabetes, liver disease, hypertension, alcohol use, smoking, education, physical activity, urine albumin-to-creatinine ratio, and nonstatin lipid-lowering medications. We assessed whether the associations differed by obesity (body mass index ≥30 kg/m2) and diabetes. All analyses were stratified by statin use. The mean age of the study population was 75.6 years; 56.1% were women, 22.9% were Black, and 52.9% were using a statin. The mean eGFR of the study population was 64.4 mL/min/1.73 m2. Individuals with an eGFR of <45 mL/min/1.73 m2 were older, more likely to be men, less educated, and less physically active, and they had a higher body mass index with more additional comorbid conditions (Table S1). Overall, neither total cholesterol nor LDL-C levels significantly differed by the levels of eGFR regardless of statin use (Fig 1A and B). Only among statin nonusers with an eGFR of <45 mL/min/1.73 m2, a lower eGFR was associated with lower total cholesterol levels (−5.6 [95% confidence interval {CI}, −1.0 to −10.3] mg/dL per −10 mL/min/1.73 m2 in eGFR). A lower eGFR was linearly associated with lower HDL-C levels in both statin users (−0.7 [95% CI, −0.5 to −1.0] mg/dL per −10 mL/min/1.73 m2 in eGFR) and nonusers (−1.2 [95% CI, −0.9 to −1.5] mg/dL per −10 mL/min/1.73 m2 in eGFR) (Fig 1C). A lower eGFR was linearly associated with higher TG levels in both statin users (6.1 [95% CI, 4.0-8.2] mg/dL per −10 mL/min/1.73 m2 in eGFR) and nonusers (6.5 [95% CI, 4.2-8.7] mg/dL per −10 mL/min/1.73 m2 in eGFR) when eGFR was 45 to 90 mL/min/1.73 m2 (Fig 1D). The results were consistent when the outcomes were analyzed as binary variables (Table 1) and when stratified by obesity or diabetes (all P values for interactions were >0.1).Table 1The Associations Between eGFR and Various Types of DyslipidemiaOutcomeStatin Users (N=2,628)Statin Nonusers (N=2,337)PrevalenceAdjustedPrevalenceAdjustedOR (95% CI)OR (95% CI)Total cholesterol ≥200 mg/dLeGFR category (mL/min/1.73 m2)>60218 (14.9%)1 (Reference)765 (52.0%)1 (Reference)45-6079 (11.5%)0.98 (0.73-1.32)267 (46.5%)1.13 (0.92-1.40)<4544 (9.2%)0.83 (0.56-1.21)102 (34.9%)0.79 (0.58-1.06)LDL-C ≥100 mg/dL>60451 (30.9%)1 (Reference)1,133 (77.0%)1 (Reference)45-60177 (25.8%)0.95 (0.76-1.19)423 (73.7%)1.04 (0.82-1.32)<45109 (22.7%)0.91 (0.69-1.19)193 (66.1%)0.86 (0.63-1.17)HDL-C <50 mg/dL>60695 (47.5%)1 (Reference)521 (35.4%)1 (Reference)45-60417 (60.8%)1.33 (1.08-1.64)aStatistically significant odds ratio with P value < 0.05.288 (50.2%)1.30 (1.03-1.63)aStatistically significant odds ratio with P value < 0.05.<45322 (67.1%)1.54 (1.19-2.00)aStatistically significant odds ratio with P value < 0.05.185 (63.4%)2.03 (1.49-2.78)aStatistically significant odds ratio with P value < 0.05.Triglycerides ≥150 mg/dL>60319 (21.8%)1 (Reference)317 (21.6%)1 (Reference)45-60200 (29.2%)1.59 (1.27-2.00)aStatistically significant odds ratio with P value < 0.05.166 (28.9%)1.41 (1.11-1.80)aStatistically significant odds ratio with P value < 0.05.<45152 (31.7%)1.68 (1.30-2.19)aStatistically significant odds ratio with P value < 0.05.92 (31.5%)1.48 (1.08-2.04)aStatistically significant odds ratio with P value < 0.05.Note: Conversion factors for units: total cholesterol, LDL-C, and HDL-C in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129.Abbreviations: CI, Confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.aStatistically significant odds ratio with P value < 0.05.a Statistically significant odds ratio with P value < 0.05. Open table in a new tab Note: Conversion factors for units: total cholesterol, LDL-C, and HDL-C in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129. Abbreviations: CI, Confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.aStatistically significant odds ratio with P value < 0.05. Our study showed a higher burden of other lipid level abnormalities, in particular low HDL-C and high TG levels, among older adults with CKD when compared with those without CKD. Previous studies have demonstrated that an elevated TG or low HDL-C level is associated with higher risk of cardiovascular events and all-cause mortality.7Zhong G.C. Huang S.Q. Peng Y. et al.HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies.Eur J Prev Cardiol. 2020; 27: 1187-1203Crossref PubMed Scopus (51) Google Scholar,8Sandesara P.B. Virani S.S. Fazio S. Shapiro M.D. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk.Endocr Rev. 2019; 40: 537-557Crossref PubMed Scopus (198) Google Scholar Patients with CKD, who have low HDL-C and elevated TG levels, may benefit from lifestyle modifications, including regular physical activity, to reduce their risk of mortality.9Ricardo A.C. Anderson C.A. Yang W. et al.Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.Am J Kidney Dis. 2015; 65: 412-424Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar The KDIGO (Kidney Disease Improving Global Outcome) guidelines strongly recommend statin use for older patients with CKD.10Wanner C. Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group MembersKDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient.Kidney Int. 2014; 85: 1303-1309Abstract Full Text Full Text PDF PubMed Scopus (396) Google Scholar Indeed, our data showed lower total cholesterol and LDL-C levels among statin users across the entire spectrum of eGFR in comparison to nonusers. Limitations to our study include the cross-sectional study design because we cannot establish temporality between kidney function and lipid levels. However, the goal of our study was to characterize lipid levels and determine the burden of dy
Abstract licence: CC BY-NC-ND
References10
10 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.